Creative Biolabs is helping researchers overcome challenges of gene therapy research by providing analytical testing ...
The drugmaker terminated the first-in-human Phase I/II trial after a year, determining that the clinical data did not support further investigation.
Boehringer Ingelheim is discarding an inhaled gene therapy designed to treat cystic fibrosis (CF) after terminating a phase 1/2 trial. | Boehringer Ingelheim is discarding an inhaled gene therapy ...
OXB to become commercial manufacturer of lentiviral vectors for Bristol Myers Squibb (BMS) CAR-T programmesMulti-year agreement with five-year ...
The MarketWatch News Department was not involved in the creation of this content. GERMANTOWN, MD AND CHICAGO, IL / ACCESS Newswire / December 16, 2025 / uBriGene Biosciences, a leading global ...
Engineered for exceptional lentiviral productivity, the 293TH line consistently delivers high titers, producing up to five times higher transduction titers than traditional adherent 293T cells. Fully ...
Overall and event-free survival of 100 and 95%, respectively, seen with autologous CD34+ hematopoietic stem-cell lentiviral gene therapy. HealthDay News — Autologous CD34+ hematopoietic stem-cell ...
The same lot of the lentiviral vector was used at both sites. The patients received nonmyeloablative conditioning with busulfan before the infusion of gene-corrected cells. Therapeutic drug monitoring ...
MILAN--(BUSINESS WIRE)--Following news on July 21 that the European Commission has granted marketing authorization for AUCATZYL® (obecabtagene autoleucel – obe-cel), AGC Biologics’ Milan site achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results